Piper Jaffray analyst Joshua Schimmer thinks that Eli Lilly (LLY) discontinuing development of its CETP inhibitor evacetrapib removes an overhang on the ongoing PCSK9 launches from Amgen (AMGN) and Regeneron (REGN) and Sanofi (SNY). Additionally, Schimmer thinks the failure of evacetrapib to show efficacy is likely mechanism specific and doesn't affect the chances of success for the ongoing PCSK9 cardiovascular outcomes studies. The analyst has an Overweight rating and $200 price target on Amgen shares.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Wells Fargo analyst Derek Archila raised the firm's price target on Annexon (ANNX) to $12 from $11 and keeps an Overweight rating on the shares. The firm believes the risk/reward remains favorable ahead of ANX005's Phase 3 data in GBS. Additionally, updates for ANX007 at ARVO, Phase 3 GBS data at PNS and read through from Sanofi's (SNY's) riliprubart in CIDP at AAN, all could offer upside for shares, Wells adds.